Domestic Weight Loss Drug 'Epe' Expected to Cost 130,000 Won for the First month... Maunzaro Half Price
4 Articles
4 Articles
The initial price of 'Epe,' an obesity drug launched by Hanmi Pharmaceutical, is expected to be around 130,000 won. With Epe joining the ranks of Wigobi and Maunzaro, price competition in the domestic obesity drug market is set to begin in earnest. According to the pharmaceutical industry on the 14th, Hanmi Pharmaceutical is reported to have set the supply price of Epe at 24,200 won per 2 mg dose. Prices are 40,700 won for 4 mg, 57,200 won for 6…
(Seoul = Yonhap News) Reporter Park Sang-hyun = Hanmi Pharmaceutical [128940] [will launch] 'E..., a glucagon-like peptide-1 (GLP-1) class obesity treatment, as early as this month.
Hanmi Pharmaceutical has set the supply price for the first month's supply of 'Efe,' a domestic obesity treatment scheduled for release this month, at 129,800 won. This is about half the price of Eli Lilly's Maunzaro, which costs approximately 270,000 won for a four-week supply based on the lowest dose (2.5 mg). With Novo Nordisk's Wigobi priced at around 210,000 won for a four-week supply, Efe has secured a lower price point than both products…
Hanmi Pharmaceutical's 'Epe', the first domestic obesity drug, is expected to be launched with a first-month treatment cost in the 120,000 won range.
Coverage Details
Bias Distribution
- 100% of the sources lean Right
Factuality
To view factuality data please Upgrade to Premium
